PAC1 RECEPTOR SIGNALING IN ESTABLISHED NEUROPATHIC PAIN: MOLECULAR MECHANISMS, NEUROINFLAMMATORY PATHWAYS, AND CENTRAL SENSITIZATION FOR TARGETED CHRONIC PAIN THERAPEUTICS
Abstract
Neuropathic pain remains one of the most refractory clinical syndromes in contemporary medicine, affecting an estimated 7–10% of the global population and representing a major unmet therapeutic challenge. Among the molecular mechanisms that underlie the transition from acute to chronic neuropathic pain, the pituitary adenylate cyclase-activating polypeptide (PACAP) and its cognate PAC1 receptor (ADCYAP1R1) have emerged as central orchestrators of both peripheral sensitization and central pain amplification. This research investigates the molecular mechanisms by which PAC1 receptor signaling sustains established neuropathic pain states, with specific focus on the cAMP–PKA–CREB and PLC–PKC–Ca²⁺ second-messenger cascades, ERK1/2 MAPK activation, neuroinflammatory cytokine production, and glial cell reprogramming in the spinal cord dorsal horn. A computational analysis of PAC1 receptor expression across eight neural tissue compartments demonstrates a 6.1- to 7.1-fold upregulation in dorsal root ganglion neurons and spinal dorsal horn, respectively, in chronic spared nerve ligation models, with statistical significance (p < 0.001) in the most strongly affected compartments relative to naïve controls.
Kinetic profiling of PAC1-coupled signaling reveals that ERK1/2 phosphorylation reaches peak amplitude at 120 minutes and sustains elevated activity through 16 hours post-stimulation, establishing the mechanistic basis for transcriptional reprogramming underlying long-term central sensitization. Neuroinflammatory cytokine heatmap analysis reveals IL-1β and COX-2 as the most robustly upregulated mediators, achieving 9.8- and 9.5-fold induction in chronic neuropathic conditions. A machine learning ensemble combining XGBoost, LSTM, and Random Forest architectures achieves an area under the receiver operating characteristic curve of 0.96 in classifying neuropathic versus sham pain states from multi-omics signatures. Therapeutic evaluation of PAC1 receptor-targeted agents identifies a novel compound achieving 88% analgesic efficacy with a safety index of 0.87. These findings collectively delineate the PAC1 receptor as a nodal therapeutic target in neuropathic pain chronification and provide a translational framework for next-generation analgesic development.
Keywords
- PAC1 receptor, PACAP, neuropathic pain, central sensitization, neuroinflammation, cAMP-PKA signaling, ERK1/2 MAPK, dorsal horn, spinal sensitization, analgesic therapeutics, machine learning pain classification, ADCYAP1R1
Views & Downloads Statistics (Last 12 Months)
Monthly performance and trends of article views and downloads
